BEVERLY HILLS, Calif.,
March 10, 2021 /PRNewswire/
-- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage
biopharmaceutical company focused on the development and
commercialization of disruptive, target-directed Natural Killer
(NK) cell engager immunotherapy protein biologic platform
technology, TriKE™, for the treatment of cancer and
infectious diseases, today announced that management will present
at the Virtual 33rd Annual Roth Conference on
Wednesday, March 17th,
2021 at 12:00 p.m. ET (9:00am PT).
A live webcast of the presentation may be accessed by visiting
the Investors section of the GT Biopharma website at
https://ir.gtbiopharma.com/. An archived replay of the webcast will
be available on the Company's website for approximately 90 days
following the presentation.
About GTB-3550 TriKE™
GTB-3550 TriKE™ is a first-in-class immuno-oncology
therapeutic being evaluated in patients age 18 and older in a Phase
I/II clinical trial (NCT03214666) having CD33+ malignancies
(primary induction failure or relapsed AML with failure of one
reinduction attempt or high-risk MDS progressed on two lines of
therapy). Interim results demonstrated GTB-3550 TriKE™
reduces bone marrow blast levels in AML and MDS patients, and
improved NK cell function and proliferation.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company
focused on the development and commercialization of immuno-oncology
therapeutic products based our proprietary TriKE™ NK
cell engager platform. Our TriKE™ platform is
designed to harness and enhance the cancer killing abilities of a
patient's immune system natural killer cells (NK cells). GT
Biopharma has an exclusive worldwide license agreement with the
University of Minnesota to further
develop and commercialize therapies using TriKE™
technology.
Forward-Looking Statements
This press release contains certain forward-looking statements
that involve risks, uncertainties and assumptions that are
difficult to predict, including statements regarding the potential
acquisition, the likelihood of closing the potential transaction,
our clinical focus, and our current and proposed trials.
Words and expressions reflecting optimism, satisfaction or
disappointment with current prospects, as well as words such as
"believes", "hopes", "intends", "estimates", "expects", "projects",
"plans", "anticipates" and variations thereof, or the use of future
tense, identify forward-looking statements, but their absence does
not mean that a statement is not forward-looking. Our
forward-looking statements are not a guarantee of performance, and
actual results could differ materially from those contained in or
expressed by such statements. In evaluating all such
statements, we urge you to specifically consider the various risk
factors identified in our Form 10-K for the fiscal year ended
December 31, 2019 in the section titled "Risk Factors" in Part
I, Item 1A and in our subsequent Form 10Q Quarterly filings with
the Securities and Exchange Commission, any of which could cause
actual results to differ materially from those indicated by our
forward-looking statements.
Our forward-looking statements reflect our current views with
respect to future events and are based on currently available
financial, economic, scientific, and competitive data and
information on current business plans. You should not place
undue reliance on our forward-looking statements, which are subject
to risks and uncertainties relating to, among other things:
(i) the sufficiency of our cash position and our ongoing
ability to raise additional capital to fund our operations,
(ii) our ability to complete our contemplated clinical trials,
or to meet the FDA's requirements with respect to safety and
efficacy, (iii) our ability to identify patients to enroll in our
clinical trials in a timely fashion, (iv) our ability to
achieve approval of a marketable product, (v) design,
implementation and conduct of clinical trials, (vii) the
results of our clinical trials, including the possibility of
unfavorable clinical trial results, (vii) the market for, and
marketability of, any product that is approved, (viii) the
existence or development of treatments that are viewed by medical
professionals or patients as superior to our products,
(ix) regulatory initiatives, compliance with governmental
regulations and the regulatory approval process, and social
conditions, and (x) various other matters, many of which are
beyond our control. Should one or more of these risks or
uncertainties develop, or should underlying assumptions prove to be
incorrect, actual results may vary materially and adversely from
those anticipated, believed, estimated, or otherwise indicated by
our forward-looking statements.
We intend that all forward-looking statements made in this press
release will be subject to the safe harbor protection of the
federal securities laws pursuant to Section 27A of the
Securities Act, to the extent applicable. Except as required
by law, we do not undertake any responsibility to update these
forward-looking statements to take into account events or
circumstances that occur after the date of this press
release. Additionally, we do not undertake any responsibility
to update you on the occurrence of any unanticipated events which
may cause actual results to differ from those expressed or implied
by these forward-looking statements.
For more information, please visit www.gtbiopharma.com.
Investors:
Julie Seidel
Stern Investor Relations, Inc.
Julie.seidel@sternir.com
212-362-1200
David Castaneda
David@gtbiopharma.com
414-351-9758
Media Relations:
Susan Roush
Susan@gtbiopharma.com
805-624-7624
View original
content:http://www.prnewswire.com/news-releases/gt-biopharma-to-present-at-the-virtual-33rd-annual-roth-conference-301244143.html
SOURCE GT Biopharma, Inc.